Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Exagen Inc.NASDAQ: XGN
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $17.31M rose 11.7% year over year, behind the +20.6% change in trailing-twelve-month revenue. Sequentially, it rose 4.1% from the prior quarter. Over 3 fiscal years it compounded at +13.5% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 6 analysts of $73.73M (+10.7%) for the fiscal year ending Dec 2026, a slowdown from the +19.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $17.31M+4.1% QoQ
- Last fiscal yearDec 2025
- $66.58M+19.7% YoY
- LTMMar 2026
- $68.38M+20.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +11.7% | +3.5% | -8.2 pp |
| 1 year | +19.7% | +10.7% | -8.9 pp |
| 3-year CAGR | +13.5% | +9.7% | -3.7 pp |
| 5-year CAGR | +11.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 66.58M USD
- Year-over-year change
- +19.7%
- 4-year CAGR
- +8.4%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 66.58M | +19.7% |
| FY2024 | 2024-12-31 | 55.64M | +5.9% |
| FY2023 | 2023-12-31 | 52.55M | +15.3% |
| FY2022 | 2022-12-31 | 45.56M | -5.7% |
| FY2021 | 2021-12-31 | 48.3M | — |
Revenue vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's LTM Mar 2026 revenue of $68.38M is the 7th highest of the 11 companies compared; the peer median is $93.53M.
- Its year-over-year change of +20.6% is the 2nd highest of 10, against a peer median of +11.2%.
- Over three fiscal years its annual growth of +13.5% compares with a peer median of +4.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $766.3M | +11.2% | +12.6% | |
| LTM Mar 2026 | $217.78M | +8.2% | -5.3% | |
| LTM Mar 2026 | $135.16M | — | +5.0% | |
| FY2025 | $107.88M | +19.8% | +42.8% | |
| LTM Mar 2026 | $107.51M | +17.4% | +31.0% | |
| LTM Mar 2026 | $79.55M | +1.8% | +2.7% | |
| LTM Mar 2026 | $68.38M | +20.6% | +13.5% | |
| LTM Mar 2026 | $41.8M | +9.3% | -0.7% | |
| LTM Mar 2026 | $31.2M | +13.4% | +4.8% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $10.32M | +611.0% | — |
| LTM Mar 2026 | $8.37M | -52.9% | -35.9% | |
| Peer median (excluding XGN) | $93.53M | +11.2% | +4.8% | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.3M | 45.56M | 52.55M | 55.64M | 66.58M |
| Cost of Revenue | 20.59M | 24.21M | 23.09M | 22.53M | 27.78M |
| Gross Profit | 27.71M | 21.35M | 29.46M | 33.11M | 38.8M |
| Gross Margin | 57.4% | 46.9% | 56.1% | 59.5% | 58.3% |
| Research & Development | 7.24M | 9.88M | 4.87M | 5.38M | 6.25M |
| Selling, General & Admin | 44.54M | 52.02M | 47.43M | 41.37M | 46.62M |
| Operating Expenses | 51.78M | 67.4M | 52.29M | 46.75M | 52.87M |
| Depreciation & Amortization | 948K | 1.56M | 2.17M | 1.72M | 2.12M |
| EBITDA | (23.1M) | (43.66M) | (19.15M) | (11.15M) | (13.46M) |
| EBITDA Margin | -47.8% | -95.8% | -36.4% | -20.0% | -20.2% |
| Operating Income | (24.07M) | (46.05M) | (22.84M) | (13.64M) | (14.07M) |
| Operating Margin | -49.8% | -101.1% | -43.5% | -24.5% | -21.1% |
| Interest Income | 16K | 830K | 1.52M | 767K | 289K |
| Interest Expense | 2.63M | 2.45M | 2.34M | 2.23M | 4.32M |
| Other Income / Expenses | (2.61M) | (1.62M) | (819K) | (1.47M) | (5.83M) |
| Income Before Tax | (26.68M) | (47.67M) | (23.66M) | (15.1M) | (19.9M) |
| Pre-Tax Margin | -55.2% | -104.6% | -45.0% | -27.1% | -29.9% |
| Income Tax Expense | 175K | (282K) | 33K | 12K | 51K |
| Net Income | (26.85M) | (47.39M) | (23.69M) | (15.12M) | (19.95M) |
| Net Margin | -55.6% | -104.0% | -45.1% | -27.2% | -30.0% |
| EPS (Basic) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| EPS (Diluted) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| Weighted Avg Shares | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
| Weighted Avg Shares (Diluted) | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.